Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China
Background: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib. Objectives: Patients with chronic phase CML receiving frontline imatin...
| Published in: | Therapeutic Advances in Hematology |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-08-01
|
| Online Access: | https://doi.org/10.1177/20406207241270806 |